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Abstract
Background: Chondroitin sulfate proteoglycans are an important mediators in inflammation and leukocyte
trafficking. However, their roles in pulmonary emphysema have not been explored.
In a murine model of elastase-induced pulmonary emphysema, we found increased carbohydrate sulfotransferase 3
(CHST3), a specific enzyme that synthesizes chondroitin 6-sulfate proteoglycan (C6SPG). To elucidate the role of
C6SPG, we investigated the effect of small interfering RNA (siRNA) targeting CHST3 that inhibits C6SPG-synthesis on
the pathogenesis of pulmonary emphysema.
Methods: Mice were intraperitoneally injected with CHST3 siRNA or negative control siRNA on day0 and 7 after
intratracheal instillation of elastase. Histology, respiratory function, glycosaminoglycans (GAGs) content,
bronchoalveolar lavage (BAL), elastin staining and gene expressions of tumor necrosis factor (TNF)-α and matrix
metalloproteinase (MMP)-9 mRNA were evaluated on day7 and/or day21.
Results: CHST3 mRNA increased at day 7 and decreased thereafter in lung. CHST3 siRNA successfully inhibited the
expression of CHST3 mRNA throughout the study and this was associated with significant reduction of GAGs and
C6SPG. Airway destruction and respiratory function were improved by the treatment with CHST3 siRNA. CHST3
siRNA reduced the number of macrophages both in BAL and lung parenchyma and also suppressed the increased
expressions of TNF-α and MMP-9 mRNA. Futhermore, CHST3 siRNA improved the reduction of the elastin in the
alveolar walls.
Conclusions: CHST3 siRNA diminishes accumulation of excessive macrophages and the mediators, leading to
accelerate the functional recovery from airway damage by repair of the elastin network associated with pulmonary
emphysema.
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Background
Cigarette smoke and pollution are primary causes of
chronic obstructive pulmonary disease (COPD). COPD
is characterized by persistent inflammation in small
airways. Emphysema with airspace enlargement due to
alveolar destruction is one of the COPD phenotypes
[1, 2]. Anti-inflammatory agents which attenuate
chronic inflammation and progression in COPD have not
been identified yet. Macrophages play a central role in
chronic inflammation occurring in COPD by producing
various inflammatory mediators, such as tumor necro-
sis factor (TNF)-α, interleukin (IL)-6, and matrix me-
talloproteinases (MMPs) [3]. To reduce the chronic
inflammation in COPD it is important to attenuate
the accumulation of macrophages and the production
of these inflammatory cytokines.
Proteoglycans, which are among the major components
of the lung cellular matrix, are important mediators in in-
flammation and leukocyte trafficking. We have reported
that deposited chondroitin sulfate proteoglycans (CSPGs)
induced recruited macrophages to contribute to chronic
inflammation and promote fibrogenesis [4]. On the other
hand in patients with mild to moderate COPD, versican,
which is known as a large CSPG, was increased [5]. In
these contexts, we hypothesize that CSPGs could be
crucial in chronic inflammation in COPD as a result of
accumulation of macrophages and reduction of deposited
CSPGs in the lung may well contribute to attenuate
emphysema.
The increased CSPGs in COPD correlate with de-
creased elastin and forced expiratory volume 1. Elastin is
crucial in maintaining elasticity in the lung. In the lung
with COPD, elastin fragmentation strongly correlates
with decreased airflow obstruction [6]. Elastin-binding
protein (EBP) chaperones tropoelastin through the Golgi
and endosomal compartments to the cell surface [7].
CSPGs bind to EBP and induce premature shedding
of EBP from the cell surface, leading to impaired
presentation of tropoelastin, and also thereby inhibit
elastin formation [8, 9]. Concerning elastin formation,
reduction in deposited CSPGs in the lung also may
be useful for attenuating development of COPD.
Carbohydrate sulfotransferase 3 (CHST3) is a specific en-
zyme that synthesizes chondroitin 6-sulfate, and transfers
sulfate to the C-6 position of the N-acetylgalactosamine
(GalNAc) residue of chondroitin. CHST3 is the key enzyme
that mediates cell migration during axonal growth in both
crushed sciatic nerves, brain development and lumbar disc
degeneration [10–12]. In addition, mutation in CHST3
results in chondrodysplasia with major involvement of the
spine [13]. However, the role of CHST3 in the development
of emphysema has not been explored.
RNA interference induced by small interfering RNA
(siRNA) has revealed sequence specific gene silencing
[14]. Recent reports show atelocollagen-mediated systemic
delivery methods for siRNA in various disease models in
vivo [15–18]. In the present study to elucidate the role of
CHST3 on the development of emphysema, we investi-
gated the effect of siRNA targeting CHST3 on murine em-
physema induced by elastase.
Methods
Mice
Female C57BL/6 (6-8-week-old) mice were obtained
from SLC Japan Inc. (Shizuoka, Japan) and bred in a
pathogen-free facility in the laboratory animal research
center at Nara Medical University. All procedures per-
formed during these animal experiments were carried
out under the control of our committee, in accordance
with The Guidelines for Animal Experiments in Nara
Medical University, and Guideline Principles for the
Care and Use of Laboratory Animals approved by The
Japanese Pharmacological Society.
Animal model
Mice were anesthetized by intraperitoneal injection with
sodium pentobarbital (50 mg/kg), and received intratra-
cheally injection of 4 units/50 μL of porcine pancreatic
elastase (PPE) (EC134; Elastin Products, Owensville,
MO) or saline alone. After PPE injection, mice were
intraperitonealy injected with 10 μg CHST3 siRNA
(Silencer Pre-designed siRNA: Cat# 16706; Ambion,
Austin, TX) or negative control siRNA (Silencer
Negative Control siRNA #1: Cat# AM4611; Ambion)
with 0.1 % atelocollagen (Koken, Tokyo, Japan) in a
200-μL volume on day 0 and 7. This protocol resulted
in the creation of 3 groups: sham mice given negative
control siRNA (sham group), PPE mice given negative
control siRNA (control group) and PPE mice treated
with CHST3 siRNA (CHST3 siRNA group).
Lung histopathology
The lung was inflated by instilling neutral-buffered 10 %
formalin to 25 cm H20. The lung volume was measured
as described previously [19, 20]. The tissue was embed-
ded in paraffin, and 4-μm thick sections were stained
with hematoxylin and eosin. The mean linear intercept
(MLI), a parameter air space enlargement, was calcu-
lated by a light microscopy on 20 randomly selected
fields as described previously [21].
Bronchoalveolar lavage
Mice were anesthetized by intraperitoneal injection with
sodium pentobarbital (50 mg/kg) and bronchoalveolar
lavage fluid (BALF) was collected by flushing the lung via
the trachea three times with 0.8 mL of sterile PBS. The
cells in the BALF were counted with a hemocytometer
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and cell differentials were determined in cytospin prepara-
tions stained with Diff-Quik products (Baxter, Miami, FL).
Antibodies and immunohistochemistry
Immunohistochemical staining was performed as pre-
viously reported [4, 22]. The following first Abs were
used: 3B3 (Seikagaku Corporation, Tokyo, Japan) for
paraffin embedded sections, F4/80 (Serotec, Oxford, UK)
and CS-56 (Seikagaku Corporation) for frozen sections
[23]. 3B3 recognizes an epitope created following chon-
droitinase ABC (ChABC) degradation of chondroitin-6
sulfate. CS-56 recognizes an epitope on some intact chon-
droitin sulfate glycosaminoglycan chains. The number of
F4/80+ cells per mm2 of alveolar wall was determined
using light microscopy, in at least 30 randomly chosen
high-power fields [4]. Immunolabeling for CS-56 and 3B3
were used Histofine kit (Nichirei Bioscience, Tokyo, Japan)
according to the manufacturer’s instructions. Tissue sec-
tions for 3B3 were pre-incubated in vitro with 0.2 U/mL
ChABC (Seikagaku Corporation) in Tris–HCl, pH 8.0, for
1 h at 37 °C.
Sulfated glycosaminoglycan (GAG) assay
The total GAG content of left lungs, harvested on day
21 after PPE administration, was determined using an
Alcian blue-binding assay for the detection of sulphated
glycosaminoglycans (WieslabAB, Lund, Sweden) accord-
ing to the manufacturer’s instructions.
Quantitative RT-PCR
Total RNA was extracted from the lung sample by
homogenization using RNA Iso plus (Takara, Shiga, Japan)
and SV total RNA isolation kit (Promega, Madison, WI)
and reverse transcribed as previously described [24]. Real-
time PCR was performed using real-time PCR DICE and
SYBR premix Taq (Takara Bio, Shiga, Japan). To calculate
the relative mRNA expression level, the expression of each
gene was normalized to that of the reference gene





TNF-α; forward; 5′- ATGGCCCAGACCCTCACA-3′,
reverse: 5′- GGAGTAGACAAGGTACAACCCATC-3′,
MMP-9; forward; 5′- CCATGCACTGGGCTTAGAT
CA-3′,
reverse: 5′- GGCCTTGGGTCAGGCTTAGA-3′,
Gapdh; forward; 5′- TGTGTCCGTCGTGGATCTGA-3′,
reverse: 5′- TTGCTGTTGAAGTCGCAGGAG-3′,
Lung compliance measurements
On day 21 after elastase administration, the mice were
anesthetized with ketamine (87 mg/kg) and xylazine
(13 mg/kg). A trachea cannula was attached to a
FlexiVent (Sireq, Montreal, Quebec, Canada) to analyze
lung function. Pressure volume curves were gener-
ated, and the static lung compliance was calculated
by the FlexiVent software.
Determination of the elastin content in the alveolar wall
Lung sections were stained with Elastica-van Gieson stain.
Stained lung sections were randomly captured three fields
(×400) microscopy (DFC280; Leica, Germany). Elastin
contents in the sections were quantified using Image J
software in blind manner. Images were converted to grey
scale. The red channel was thresholded to exclusively
reveal the blue-black stained elastic fibers. The total
elastin positive pixels were expressed as a percentage of
total tissue area as previously described [25].
Statistical analysis
Differences were evaluated using Student’s t-test. p-values
< 0.05 were considered to indicate statistically significant
differences.
Results
CHST3 siRNA protects against elastase-induced lung
emphysema
Morphometric assessment was performed on days 7 and
21 after PPE administration. In the control siRNA group,
the development of airspace enlargement with progressive
destruction of alveolar walls was observed from day 7.
However, administration of CHST3 siRNA attenuated the
histologic changes in mice given PPE from day 7 (Fig. 1a).
We examined the enlargement of the airspaces quantify-
ing the MLI on days 0, 7 and 21. MLI increase was
observed in the control siRNA group compared with the
sham group from day 7. The increase was significantly
attenuated by CHST3 siRNA from day 7 (Fig. 1b).
Effect of CHST3 siRNA on pulmonary function
The lung volume was significantly increased in the control
siRNA on day 21 after PPE administration. CHST3 siRNA
significantly attenuated the increase in lung volume
(Fig. 2a). To test the effect of CHST3 siRNA on lung
dysfunction, static lung compliance (Cst) was assessed.
PPE administration significantly enhanced Cst compared
with the Sham group. CHST3 siRNA treated mice pre-
vented the increase in Cst (Fig. 2b). These data demon-
strate that CHST3 siRNA has a beneficial effect on
respiratory function.
CHST3 siRNA effectively inhibited the expression of
CHST3 expression in vivo
In order to elucidate the role of CHST3 in lung inflam-
mation and emphysema, we examined CHST3 expres-
sion on days 0, 7 and 21 after PPE-induced lung injury.
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Fig. 1 Morphometric assessment after porcine pancreas elastase (PPE) administration. a Hematoxylin-eosin (HE) staining of lung tissue 21 days
after PPE administration. PPE induced the development of airspace enlargement with destruction of the alveolar walls (Control siRNA). CHST3
siRNA attenuated emphysematous change (CHST3 siRNA). Scale bar 200 μm. b Semiquantative analysis of lung tissue using the mean linear
intercept (MLI). n = 5. *p < 0.01 versus sham group. †p < 0.01 versus control siRNA group
Fig. 2 Lung volume and Static lung compliance (Cst) values after PPE administration. a Effect of CHST3 siRNA on lung volume 21 days after PPE
administration. PPE significantly increased lung volume. CHST3 siRNA suppressed the change. (n = 5 per group). *p < 0.01 versus sham group.
†p < 0.01 versus control siRNA group. b Effect of CHST3 siRNA on lung mechanics day21 after PPE administration. PPE significantly increased Cst.
CHST3 siRNA suppressed the change. (n = 5 per group). ‡p < 0.05 versus sham group. †p < 0.01 versus control siRNA group
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After PPE administration, the expression of CHST3 was
increased in lung tissue on days 7 and 21. CHST3 siRNA
inhibited effectively suppressed the expression of CHST3
on days 7 and 21 (Fig. 3).
Increased deposition of CSPGs in the elastase-induced
emphysema model
We investigated immunohistochemically deposited CSPGs
in the injured lung using mAb CS-56 which recognizes an
epitope on intact CSPGs chains. CSPGs were barely
detectable in normal lungs, but were clearly present on
the alveolar wall 21 days after PPE challenge. CHST3
siRNA treatment effectively reduced deposited CSPGs
(Fig. 4a). MAb 3B3 recognizes an epitope created follow-
ing the degradation of chondroitin-6 sulfate by ChABC.
Chondroitin 6-sulfate proteoglycan (C6SPG) also in-
creased on alveolar wall after PPE challenge on day 21.
However, CHST3 siRNA treatment significantly reduced
deposited C6SPG (Fig. 4b).
Deposited GAGs were directly evaluated in the left
lungs using a sulphated GAGs assay. In mice treated
with PPE, GAGs level had increased 2.2-fold by day 21
compared to the sham group. CHST3 siRNA treatment
significantly reduced deposited GAGs, thus confirming
its in vivo efficacy (Fig. 4c).
CHST3 siRNA prevent inflammation after PPE administration
To investigate the effect of CHST3 siRNA in the inflam-
matory response to PPE induced injury, we assessed the
number of inflammatory cells in the BALF collected
from mice after PPE challenge. Intratracheal PPE admin-
istration significantly increased the total number of cells
and macrophage count in the BALF. CHST3 siRNA
treated mice followed a similar pattern, but was signifi-
cantly reduced in number of the experiment compared
with BALF cells from control siRNA treated mice
(Fig. 5a, b).
Inhibited accumulation of F4/80+ macrophages by
CHST3 siRNA
We next investigated the time-course of the appearance
of F4/80+ macrophages in the lung parenchyma on days
0, 7, and 21. In control siRNA treated mice, a massive
accumulation of F4/80+ cells was detected on day 7 after
PPE challenge and slightly decreased by day 21. However,
CHST3 siRNA induced a significantly increased influx of
F4/80+ cells at all time points (Fig. 6a, b). These data
demonstrate that CHST3 siRNA prevents the accu-
mulation of macrophages in the lung parenchyma in
response to PPE challenge.
CHST3 siRNA inhibited TNF-α and MMP-9 expression in
vivo after PPE administration
Since TNF-α and MMP-9 play important roles in the
pathogenesis of emphysema, we examined their expres-
sions in lung tissue. The TNF-α and MMP-9 levels were
markedly increased in PPE-treated mice on day 7, and
treatment with CHST3 siRNA significantly reduced the
TNF-α and MMP-9 expression in lung tissues (Fig. 7a, b).
CHST3 siRNA improved the reduction the elastin of the
alveolar walls
Elastica-van Gieson staining showed reduced elastin
staining in the alveolar wall of control group lung com-
pared with normal lung (Fig. 8a). Quantification was per-
formed using Image J software by measuring % elastin
area of alveolar walls. Control group mice had significantly
lower levels of elastin detected within alveolar wall
compared with normal mice from day 7. CHST3 siRNA
treatment suppressed the decreased of % area of elastin
on day21 (Fig. 8b, c).
Discussion
Alveolar macrophages play a pivotal role in the patho-
physiology of COPD [3]. The presence of macrophages
is the main factor involved in emphysema because they
release inflammatory mediators such as TNF-α, IL-6,
and MMPs at the injury site. The persistence of macro-
phages at the injured area has been thought to be associ-
ated with the development of chronic inflammation and
lung emphysema. We previously demonstrated that
CSPGs were upregulated in a murine model of the lung
with bleomycin-induced pulmonary fibrosis. Deposited
CSPGs retained macrophages in fibrotic interstitium in a
CD44-dependent manner. In addition, digestion of
CSPGs by CSPG-digesting enzyme ChABC increased
survival and reduced fibrosis by inhibiting persistent
macrophage accumulation [4]. In this study, we demon-
strated that reduced deposited C6SPG by CHST3 siRNA
treatment impaired the accumulation of macrophages in
BALF and in lung parenchyma (Figs. 5 and 6). Moreover
this treatment decreased MLI and prevented an increase
Fig. 3 Real time quantitative PCR analysis of CHST3 mRNA in the
lung. Total RNA was isolated from lung tissues on days 0, 7 and 21
after PPE administration. (n = 5 per group). *p < 0.01 versus the Sham
group. †p < 0.01 versus the Control siRNA group
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in lung volume and lung compliance (Figs. 1 and 2).
Therefore, the present study indicates an important role
of CSPGs for the development of emphysema induced
by elastase injection.
CSPGs have been recognized as playing an important
roles in cell adhesion, proliferation, tissue morphogen-
esis, neurite outgrowth, infections, and inflammation/
leukocyte trafficking [26, 27]. Chondroitin sulfate (CS)
chains are found as proteoglycan side chains in the
extracellular matrices and at cell surface, and the main
components of cartilage consisting of repeating disacchar-
ide units sulfated either at the C-6 or the C-4 position of
the GalNAc. Versican, which is large chondroitin sulfate
proteoglycan, is a structural component of the ECM and a
Fig. 4 Immunohistochemical detection of CSPGs and Glycosaminoglycans (GAGs) content on days 21 after PPE administration. a CS-56 recognizes
an epitope on intact chondroitin sulfate glycosaminoglycan chains. CS-56 immunolabeling indicated that CHST3 siRNA treatment suppressed the
increased chondroitin sulfate after PPE administration. b 3B3 recognizes an epitope created following the degradation of chondroitin-6 sulfate by
ChABC. 3B3 immunolabeling indicated that CHST3 siRNA treatment suppressed the increased chondroitin-6 sulfate after PPE administration. Boxes
indicate CS-56 or 3B3 staining in alveolar walls. Inserts show high magnification of boxes. Scale bar 100 μm. c GAGs content of the left lung on
day 21 after PPE administration. (n = 5 per group). Mean ± SD, *p < 0.01 versus the Sham group. †p < 0.01 versus the Control siRNA group
Fig. 5 Infiltration of total cells and macrophages in bronchoalveolar lavage fluid (BALF) after PPE administration. CHST3 siRNA treatment significantly
reduced the number of (a) total cells and (b) macrophages in the BALF after PPE administration. (n = 5 per group). Mean ± SD, *p < 0.01, †p < 0.05
versus the Sham group. ‡p < 0.01 §p < 0.05 versus the Control siRNA group
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molecule that interacts with cells. In addition, Versican
plays important roles in leukocyte adhesion and activation.
In COPD, the modulation of versican influences elastic
fiber deposition [28, 29]. CHST3, the gene encoding chon-
droitin 6-sulphotransferase-1, catalyzes modifying step of
CS synthesis by transferring sulfate to the C-6 position of
the GalNAc of chondroitin [30]. CHST3 is up-regulated in
injured central nervous system (CNS) and inhibits axonal
regeneration [31]. CHST3 is a key enzyme that mediates
schwann cell migration during axonal growth [10]. In con-
trast, CSPGs in the inflammatory processes of various
chronic inflammatory diseases in vivo have not been re-
ported. To identify the in vivo role of CSPGs in a pulmonary
emphysema model, we used the atelocollagen-mediated sys-
temic delivery method for siRNA targeting CHST3. In the
present study, we found upregulated expression of CHST3
mRNA after elastase challenge. Administration of CHST3
siRNA could reduce the CHST3 level in lung (Fig. 3). In
addition, immunocytochemistry indicated deposited CSPGs,
specially C6SPG were seen diffusely in the alveolar wall after
elastase challenge. CHST3 siRNA successfully resulted in
the limitation of CSPGs and C6SPG (Fig. 4).
Fig. 6 Infiltration of F4/80+ macrophages in lung parenchyma after PPE administration. a Immunohistochemical detection of F4/80 in untreated
lung (d0) or 7 or 21 days after PPE administration. Scale bar 100 μm. b Quantitative analysis of F4/80+ macrophages in the alveolar area. *p < 0.01
versus the Sham group. †p < 0.01 versus the Control siRNA group
Fig. 7 Kinetics of TNF-α and MMP-9 mRNA after PPE administration. Real time quantitative PCR analysis of (a) TNF-α, (b) MMP-9 mRNA in the lung.
Total RNA was isolated from lung tissues on days 0, 7, and 21 after PPE administration. (n = 5 per group). *p < 0.05 versus the Sham group.
†p < 0.05 versus the Control siRNA group
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During the early inflammatory phase (day 7), CHST3
siRNA reduced the number of F4/80+ macrophages in lung
parenchyma and macrophages in BAL (Figs. 5 and 6). In
addition, the expression of TNF-α and MMP-9 were sup-
pressed significantly by CHST3 siRNA (Fig. 7). Based on
previous reports, MMP-9 secretion is increased in alveolar
macrophages from COPD patients compared to smokers
without the disease [32]. MMP-9 transgenic mice devel-
oped significant air space enlargement associated with the
loss of alveolar elastin [33]. Macrophages release a variety
of inflammatory mediators including TNF-α and IL-1β as
well as MMPs, including MMP-9 and MMP-12. MMP-9
production in human monocyte/macrophages is related
to autocrine stimulation by TNF-α [34]. In addition,
TNF-α can be released in vitro by the proteolytic ac-
tion of MMPs, including MMP-9 [35]. MMP-9, pro-
duced by the activated macrophages, has the ability
to cleave elastin with a majority of emphysema pro-
gressive. Elastin fragments, degradation of elastin by
MMPs, promote the accumulation of monocytes from the
circulation into lung tissue [36]. Thus, C6SPG directly
regulates the accumulation of macrophages and the ex-
pression of TNF-α and MMP-9. In addition, Anti-
inflammatory effect by C6SPG-synthesis block the feed-
back loops by elastin fragment.
During the late phase (Day 21), F4/80+ macrophages
were still detected in the lung parenchyma, despite the
decrease in mediators, TNF-α and MMP-9. This result
suggests that the recruitment of macrophages in the late
phase may be less dependent on elastin fragmation by
MMP-9 than on other factors that may play a key role in
the progression from inflammation to emphysema. We
previously demonstrated that deposited CSPGs retained
macrophages in fibrotic interstitium in a CD44-dependent
Fig. 8 CHST3 siRNA improved the reduction of the elastin in the alveolar walls. a Elastica-van Gieson staining of the alveolar wall in untreated lung
(d0) or 7 or 21 days after PPE administration. Elastin appeared as distinct blue-black lines through the alveolar walls. Boxes indicate deposition of elastin
in alveolar walls. Inserts show high magnification of boxes. Cont siRNA mice on day7 and 21 show discontinuous elastin deposition in walls. CHST3
siRNA mice on day7 and 21 show continuous elastin deposition. Scale bar 100 μm. b Images show the area occupied by elastic fibers using imaging
software, Image J (red area). c Quantification of alveolar wall elastin. Control group mice had significantly lower levels of elastin detected within alveolar
walls compared with untreated lung from day 7. CHST3 siRNA treatment suppressed the decreased levels of elastin on day 21. (n = 5 per group).
*p < 0.01 versus the Sham group. †p < 0.01 versus the Control siRNA group
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manner in a bleomycin-induced pulmonary fibrosis model
[4]. Thus, in this study, prolonged deposition of C6SPG
might be responsible for retaining recruited macrophages
within the interstitium. Blockage of C6SPG-synthesis
prevents increased deposited C6SPG, which acted as a
scaffold of macrophages, and diminishes accumulation of
macrophages. Significant increase in MLI was already
observed at day 7 and increased at day 21 in control mice.
By contrast, CHST3 siRNA prevented the increase of
MLI. Moreover, lung function by CHST3 siRNA was
recovery to sham group.
CSPGs in the alveolar wall in COPD patients are nega-
tively correlated to elastin and EBP [5]. CSPGs inhibit effi-
cient repair by inhibiting re-synthesis of elastic fibers in
alveoli of COPD patients. We reasoned that deposited
CSPGs inhibit the elastin recovery from airway damage
also in the elastase-induced pulmonary emphysema model
[8, 9]. Elastic fiber in the alveolar wall of control siRNA re-
duced on day 7 and further on day 21. Although the re-
duction of elastic fiber in CHST3 siRNA was observed on
day 7, CHST3 siRNA recovered the reduction of elastic
fiber after day 21 (Fig. 8). Thus, CHST3 siRNA suppressed
the progressive destruction of the elastin and rather, in-
duced the lung recovery by promoting elastic repair.
Based on these observations, we propose the role of
CSPGs in elastase-induced pulmonary emphysema model
(Fig. 9). In the inflammatory phase, CHST3-mediated
C6SPG regulates macrophage recruitment and augments
TNF-α and MMP-9 activities. These mediators lead to
elastic fiber destruction with production of elastin frag-
ment. Furthermore, these fragments in turn lead to the
macrophage accumulation. CSPGs act as a scaffold of
macrophages. The malignant cycle by elastin fragments
contributes to emphysema progression. CHST3 siRNA
breaks this cycle, resulting in amelioration from chronic
inflammation to emphysema.
In the regeneration phase, CHST3-mediated C6SPG
inhibits repair of elastin. CHST3 siRNA accelerates the
elastin recovery.
One of the limitations of this study is that we did not
evaluate the effect of cigarette smoke exposure. Cigarette
smoke exposure models are more similar to human
pulmonary emphysema and are scheduled in future.
COPD has been recognized as a systemic disease based
on systemic inflammation [37]. In present study, we there-
fore used the systemic delivery method. It is known that a
loss of CHST3 function results in human chondrodyspla-
sia. Local administration of siRNA intratracheally may be
more important than systemic administration.
Conclusions
CHST3 siRNA treatment significantly reduced macro-
phage accumulation and the mediators. Furthermore,
CHST3 siRNA accelerated the functional recovery from
airway damage by repair of the elastin network. This
finding that CHST3 siRNA prevents chronic lung
inflammation and emphysema might be of use in the
development of new therapeutic approaches for chronic
inflammatory disease.
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